WO2007068621A1 - Nouveaux dérivés de pyrrole à cycles fusionnés - Google Patents

Nouveaux dérivés de pyrrole à cycles fusionnés Download PDF

Info

Publication number
WO2007068621A1
WO2007068621A1 PCT/EP2006/069292 EP2006069292W WO2007068621A1 WO 2007068621 A1 WO2007068621 A1 WO 2007068621A1 EP 2006069292 W EP2006069292 W EP 2006069292W WO 2007068621 A1 WO2007068621 A1 WO 2007068621A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
fluoro
indole
carboxylic acid
ylmethyl
Prior art date
Application number
PCT/EP2006/069292
Other languages
English (en)
Inventor
David Banner
Hans Hilpert
Bernd Kuhn
Harald Mauser
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37782002&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2007068621(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to BRPI0619963-1A priority Critical patent/BRPI0619963A2/pt
Priority to NZ568594A priority patent/NZ568594A/en
Priority to CA002637740A priority patent/CA2637740A1/fr
Priority to EP06841282.4A priority patent/EP1966134B1/fr
Priority to AU2006326136A priority patent/AU2006326136B2/en
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Priority to JP2008544957A priority patent/JP4955012B2/ja
Priority to CN2006800471484A priority patent/CN101351446B/zh
Priority to KR1020087014264A priority patent/KR101355754B1/ko
Publication of WO2007068621A1 publication Critical patent/WO2007068621A1/fr
Priority to IL191768A priority patent/IL191768A0/en
Priority to NO20082561A priority patent/NO20082561L/no
Priority to HK09106622.4A priority patent/HK1127058A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Definitions

  • the invention is concerned with novel fused pyrrole derivatives of formula (I),
  • A is benzene ring or heteroaryl ring, which is a monocyclic aromatic ring of 5 to 6 ring atoms having one, two, or three ring heteroatoms selected from N, O, and S, the remaining ring atoms being C;
  • Ar is naphthalenyl, or heteroaryl, which is a bicyclic aromatic radical of 8 to 10 ring atoms having at least one aromatic ring containing one, two, or three ring heteroatoms selected from N, O, and S, the remaining ring atoms being C, said naphthalenyl and heteroaryl being optionally substituted by one to three substituents independently selected from the group consisting of C 1-6 alkyl, C 3 - 7 cycloalkyl, C3-7 cycloalkyl C 1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, hydroxy, C 1-6 alkoxy, halogen, heteroalkyl, heteroalkoxy, nitro, cyano, amino and mono- or di-C 1-6 alkyl substituted amino;
  • R 1 is hydrogen, halogen, C 1-6 alkyl, C 1-6 alkoxy, carboxyl, nitro, cyano, amino, mono- or di-C 1-6 alkyl substituted amino, heteroalkyl, heteroalkoxy, C 3 - 7 cycloalkyl, C3-7 cycloalkyl C 1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, hydroxy, C 1-6 alkoxy, optionally substituted heterocyclyl-Ci-6 alkyl, optionally substituted heterocyclylcarbonyl-Ci-6 alkyl, optionally substituted phenyl-Ci-6 alkyl, optionally
  • R 1 is N(R')(R"), N(R')(R")-Ci-6 alkyl- or N(R')(R")-carbonyl-Ci_ 6 alkyl-, in which R' and R" are independently selected from the group consisting of hydrogen, Ci_6 alkyl, C3-7 cycloalkyl, C3-7 cycloalkyl Ci_6 alkyl, C2-6 alkenyl, C2-6 alkynyl, heteroalkyl, optionally substituted phenyl Ci_ 6 alkyl, optionally substituted heteroaryl Ci_ 6 alkyl, optionally substituted heterocyclyl Ci_ 6 alkyl, optionally substituted phenylcarbonyl, optionally substituted heteroarylcarbonyl and optionally substituted heterocyclylcarbonyl; or
  • R 1 is R'-CO-N(R")-Ci_6 alkyl-, R'-O-CO-N(R")-Ci_ 6 alkyl-, R'-SO 2 - N(R")-Ci_6 alkyl- or (R')(R")N-SO 2 -N(R'")-C 1-6 alkyl-, in which R', R" and R'" are independently selected from the group consisting of hydrogen, C 1-6 alkyl, C 3 - 7 cycloalkyl, C3-7 cycloalkyl C 1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, heteroalkyl, optionally substituted phenyl, optionally substituted heteroaryl, optionally substituted heterocyclyl, optionally substituted phenyl C 1-6 alkyl, optionally substituted heteroaryl C 1-6 alkyl and optionally substituted heterocyclyl C 1-6 alkyl;
  • R 2 , R 2 and R 2 are independently hydrogen, halogen, cyano, nitro, amino, mono- or di-C 1-6 alkyl substituted amino, C 1-6 alkyl, C 3 - 7 cycloalkyl, C 3 - 7 cycloalkyl C 1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, heteroalkyl, hydroxy , C 1-6 alkoxy or heteroalkoxy;
  • n is an integer of 0 to 4.
  • R 1 is preferably hydrogen, halogen, C 1-6 alkyl, C 1-6 alkoxy, carboxyl, nitro, cyano, amino, mono- or di-C 1-6 alkyl substituted amino, heteroalkyl, heteroalkoxy, C3-7 cycloalkyl, C3-7 cycloalkyl C 1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, hydroxy, C 1-6 alkoxy, optionally substituted heterocyclyl-Ci-6 alkyl, optionally substituted heterocyclylcarbonyl-Ci-6 alkyl, optionally substituted phenyl-Ci-6 alkyl, optionally substituted phenylcarbonyl-Ci-6 alkyl, optionally substituted heteroaryl-Ci-6 alkyl, optionally substituted heteroarylcarbonyl-Ci-6 alkyl or heteroalkoxy-Ci-6 alkyl, or
  • R 1 is N(R')(R"), N(R')(R")-Ci-6 alkyl- or N(R')(R")-carbonyl-Ci_ 6 alkyl-, in which R' and R" are independently selected from the group consisting of hydrogen, C 1-6 alkyl, C3-7 cycloalkyl, C3-7 cycloalkyl C 1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, heteroalkyl, optionally substituted phenyl C 1-6 alkyl, optionally substituted heteroaryl C 1-6 alkyl, optionally substituted heterocyclyl C 1-6 alkyl, optionally substituted phenylcarbonyl, optionally substituted heteroarylcarbonyl and optionally substituted heterocyclylcarbonyl; or
  • R 1 is R'-O-CO-N(R")-Ci_6 alkyl-, R'-SO 2 -N(R")-Ci_ 6 alkyl- or (R')(R")N- SO 2 -N(R'")-Ci_6 alkyl-, in which R', R" and R'" are independently selected from the group consisting of hydrogen, C 1-6 alkyl, C 3 - 7 cycloalkyl, C 3 - 7 cycloalkyl C 1-6 alkyl, C 2 -6 alkenyl, C 2 -6 alkynyl, heteroalkyl, optionally substituted phenyl, optionally substituted heteroaryl, optionally substituted heterocyclyl, optionally substituted phenyl C 1-6 alkyl, optionally substituted heteroaryl C 1-6 alkyl and optionally substituted heterocyclyl C 1-6 alkyl.
  • the invention is concerned with a process and an intermediate for the manufacture of the above compounds, pharmaceutical preparations which contain such compounds, the use of these compounds for the production of pharmaceutical preparations as well as a process for the manufacture of the intermediate.
  • Chymase is a serine proteinase with an expression pattern striktly limited to a sub-population of mast cells (M CT mast cell). Chymase is activated only upon mast cell activation and degranulation which restricts the enzyme activity to M CT positive tissues. Chymase is specifically cleaving a number of pathologically relevant substrates (Raymond, W. W., S. W. Ruggles, et al.; JBC 2003 278(36): 34517-34524) whereby it can activate Angiotensin II, Endothelin, TGFb, 111, SCF, collagenase and degrade proteins like Thrombin, FN, APO Al ,2.
  • the present invention provides the novel compounds of formula (I) which are chymase inhibitors.
  • halogen or halo means fluorine, chlorine, bromine and iodine, with fluorine, chlorine and fluorine being preferred.
  • C 1-6 alkyl alone or in combination with other groups, means a branched or straight-chain monovalent alkyl radical, having one to six carbon atoms. This term is further exemplified by such radicals as methyl, ethyl, n-propyl, isopropyl, n-butyl, s-butyl, t-butyl. C 1-4 alkyl is more preferred.
  • heteroalkyl means C 1-6 alkyl substituted by one or more substituents selected independently from the group consisting of nitro, hydroxy, halogen, cyano, C 1-6 alkoxy, formyl, C 1-6 alkylcarbonyl, carboxyl, C 1-6 alkylthio, C 1-6 alkyl sulfinyl, C 1-6 alkyl sulfonyl, carbamoyl, amino and mono- or di- C 1-6 alkyl substituted amino.
  • This term is further exemplified by such radicals as 2-hydroxyethyl, perfluoromethyl.
  • C 1-6 alkyl substituted by one hydroxy group, one carboxyl group, one carbamoyl group, one C 1-6 alkoxy group or one to three same or different halogen atoms are preferred.
  • heteroalkoxy means heteroalkyl-O-.
  • hydroxy C 1-6 alkyl means C 1-6 alkyl substituted by one or more, preferably one hydroxy group (s) .
  • hydrocarbon radical of three to seven ring carbons, e.g., cyclopropyl, cyclobutyl, cyclohexyl.
  • C 1-6 alkoxy alone or in combination with other groups, means the group R'-O-, wherein R' is a C 1-6 alkyl.
  • C 2 - 6 alkenyl alone or in combination with other groups, means a straight-chain or branched hydrocarbon residue comprising an olefinic bond, having two to six carbon atoms, such as e.g. ethenyl, 2-propenyl.
  • d- ⁇ -alkynyl alone or in combination with other groups, means a straight-chain or branched hydrocarbon residue comprising a tripple bond, having two to six carbon atoms, such as e.g. ethynyl, 2-propynyl.
  • heterocyclyl alone or combination with other groups, means non- aromatic monocyclic radicals of three to eight ring atoms in which one or two ring atoms are heteroatoms selected from N, O, or S(O) n (where n is an integer from 0 to 2), the remaining ring atoms being C.
  • heteroaryl alone or combination with other groups, means a monocyclic aromatic radical of five to eight ring atoms, containing one, two, or three ring heteroatoms selected from N, O, and S, the remaining ring atoms being C.
  • optionally substituted phenyl means, alone or combination with other groups, respectively phenyl, heteroaryl and heterocyclyl optionally substituted by one or more substituents independently selected from the group consisting of halogen, nitro, cyano, amino, C 1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, hydroxy, C 1-6 alkoxy, mono- or di- C 1-6 alkyl substituted amino, heteroalkyl and heteroalkoxy.
  • bicyclic aromatic radical means a radical having two aromatic rings which are fused to each other.
  • compositions of formula (I) can form pharmaceutically acceptable acid addition salts.
  • pharmaceutically acceptable salts are salts of compounds of formula (I) with physiologically compatible mineral acids, such as hydrochloric acid, sulphuric acid, sulphurous acid or phosphoric acid; or with organic acids, such as methanesulphonic acid, p-toluenesulphonic acid, acetic acid, lactic acid, triflu or o acetic acid, citric acid, fumaric acid, maleic acid, tartaric acid, succinic acid or salicylic acid.
  • physiologically compatible mineral acids such as hydrochloric acid, sulphuric acid, sulphurous acid or phosphoric acid
  • organic acids such as methanesulphonic acid, p-toluenesulphonic acid, acetic acid, lactic acid, triflu or o acetic acid, citric acid, fumaric acid, maleic acid, tartaric acid, succinic acid or salicylic acid.
  • Compounds of formula (I) in which a COOH group is present can further form salts with bases.
  • salts are alkaline, earth-alkaline and ammonium salts such as e.g. Na-, K-, Ca- and Trimethylammoniumsalt.
  • pharmaceutically acceptable salts also refers to such salts. Acid addition salts as described above are preferred.
  • aryl group optionally substituted with an alkyl group means that the alkyl may but need not be present, and the description includes situations where the aryl group is substituted with an alkyl group and situations where the aryl group is not substituted with the alkyl group.
  • “Pharmaceutically acceptable excipient” means an excipient that is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable, and includes excipient that is acceptable for veterinary use as well as human pharmaceutical use.
  • a "pharmaceutically acceptable excipient” as used in the specification and claims includes both one and more than one such excipient.
  • isomers Compounds that have the same molecular Formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are termed “isomers.” Isomers that differ in the arrangement of their atoms in space are termed “stereoisomers”. Stereoisomers that are not mirror images of one another are termed “diastereomers” and those that are non-superimposable mirror images of each other are termed “enantiomers”. When a compound has an asymmetric center, for example, if a carbon atom is bonded to four different groups, a pair of enantiomers is possible.
  • An enantiomer can be characterized by the absolute configuration of its asymmetric center and is described by the R- and S- sequencing rules of Cahn, In gold and Prelog, or by the manner in which the molecule rotates the plane of polarized light and designated as dextrorotatory or levorotatory (i.e., as (+) or (-)-isomers respectively).
  • Achiral compound can exist as either individual enantiomer or as a mixture thereof. A mixture containing equal proportions of the enantiomers is called a "racemic mixture".
  • the compounds of formula (I) can possess one or more asymmetric centers. Unless indicated otherwise, the description or naming of a particular compound in the specification and claims is intended to include both individual enantiomers and mixtures, racemic or otherwise, thereof, as well as individual epimers and mixture thereof.
  • the methods for the determination of stereochemistry and the separation of stereoisomers are well-known in the art (see discussion in Chapter 4 of "Advanced Organic Chemistry", 4th edition J. March, John Wiley and Sons, New York, 1992).
  • a preferred compound of the invention is a compound of formula (I), wherein A is a benzene ring or a pyridine ring, preferably a benzene ring.
  • Another preferred compound of the invention is a compound of formula (I) , wherein Ar is naphthalenyl or heteroaryl, which is a bicyclic aromatic radical of 8 to 10 ring atoms, containing one to three ring heteroatoms selected from O, N and S, the remaining ring atoms being C, said naphthalenyl and heteroaryl being optionally substituted by one to three substituents independently selected from the group consisting of C 1-6 alkyl, C 1-6 alkoxy and halogen.
  • Ar is naphthalenyl or heteroaryl, which is a bicyclic aromatic radical of 8 to 10 ring atoms, containing one to three ring heteroatoms selected from O, N and S, the remaining ring atoms being C, said naphthalenyl and heteroaryl being optionally substituted by one to three substituents independently selected from the group consisting of C 1-6 alkyl, C 1-6 alkoxy and halogen.
  • a preferred heteroaryl is a bicyclic aromatic radical of 9 ring atoms, containing one ring heteroatom selected from O, N and S, the remaining ring atoms being C, which is optionally substituted by one to three substituents independently selected from the group consisting Of C 1- 6 alkyl, C 1-6 alkoxy and halogen.
  • Another preferred compound of the invention is a compound of formula (I) , wherein n is an integer of 1 to 4, more preferably 1.
  • Another preferred compound of the invention is a compound of formula (I) , wherein R 1 is hydrogen, halogen, C 1-6 alkyl, C 1-6 alkoxy, carboxyl, optionally substituted heterocyclyl-Ci-6 alkyl, optionally substituted heterocyclylcarbonyl-Ci-6 alkyl or heteroalkyl, or
  • R 1 is N(R')(R")-(Ci-6 alkylene)- or N(R')(R")-carbonyl-Ci_ 6 alkyl-, in which R' and R" are independently selected from the group consisting of hydrogen, C 1-6 alkyl, heteroalkyl, optionally substituted phenyl C 1-6 alkyl and optionally substituted phenylcarbonyl, more preferably R 1 is hydrogen, C 1-6 alkyl, carboxyl C 1- 6 alkyl, hydroxy C 1-6 alkyl, C 1-6 alkoxy C 1-6 alkyl, carboxyl, or N(R')(R")-carbonyl- C 1-6 alkyl-, in which R' and R" are independently selected from the group consisting of hydrogen and C 1-6 alkyl.
  • R 1 is especially hydrogen, methyl, carboxylmethyl, dimethylaminocarbonylmethyl or 2-methoxyethyl.
  • Another preferred compound of the invention is a compound of formula (I) , wherein R 1 is R'-O-CO-N(R")-C 1-6 alkyl-, R'-SO 2 -N(R")-Ci_ 6 alkyl- or (R')(R")N- SO 2 -N(R'")-Ci_6 alkyl-, in which R', R" and R'" are independently selected from the group consisting of hydrogen and C 1-6 alkyl.
  • Another preferred compound of the invention is a compound of formula (I) , wherein one of R 2 , R 2 and R 2 is hydrogen and the other two are independently hydrogen, halogen, C 1-6 alkyl, hydrogenated C 1-6 alkyl or C 1-6 alkoxy, more preferably two of R 2 , R 2 and R 2 are hydrogen and the other is hydrogen or halogen. Fluorine is preferred as halogen.
  • Another preferred compound of the invention is a compound of formula (I) , which are
  • A, Ar, R 2 and R 2 and n are as described before in the broadest definition of this invention.
  • A, Ar, R 2 and R 2 and n are preferably as described in i) to iv) above.
  • Ar is more preferably naphthalenyl.
  • R 1 is more preferably hydrogen, carboxyl Ci_6 alkyl or Ci_6 alkoxy Ci_6 alkyl.
  • R , R and R are more preferably hydrogen.
  • Another preferred compound of the invention is a compound of formula (I) , which are
  • A, Ar, R 2 and R 2 and n are as described before in the broadest definition of this invention.
  • A, Ar, R 2 and R 2 and n are preferably as described in i) to iv) above.
  • R 1 is more preferably hydrogen, Ci_ 6 alkyl, carboxyl Ci_ 6 alkyl, hydroxy Ci_6 alkyl, carboxyl, or N(R')(R")- car t>onyl-Ci_6 alkyl-, in which R' and R" are independently selected from the group consisting of hydrogen and Ci_ 6 alkyl.
  • Another preferred compound of the invention is a compound of formula (I) , which is
  • Another preferred compound of the invention is a compound of formula (I), which is
  • the compounds of the present invention can be prepared, for example, by the general synthetic procedures described below.
  • R a is methyl or ethyl.
  • X is chloro, bromo or iodo.
  • Coupling of the indoles (V) and the halogen-methyl derivatives (IV) can be accomplished with a base, e.g. IiH, KH or preferably NaH in a solvent like tetrahydrofurane or preferably dimethylformamide at 0 0 C to 100 0 C, preferably at 20 0 C to 60 0 C to give the indole ester (VI).
  • a base e.g. IiH, KH or preferably NaH in a solvent like tetrahydrofurane or preferably dimethylformamide at 0 0 C to 100 0 C, preferably at 20 0 C to 60 0 C to give the indole ester (VI).
  • Hydrolysis of the ester (VI) can be effected with IiOH, KOH or preferably NaOH in a solvent like H 2 O, MeOH or tetrahydrofurane, preferably in a mixture of H 2 O, andMeOH to afford the compounds of formula (F).
  • Halogen-methyl derivatives (IV), in which Ar is naphthalenyl, if not commercially available, can be prepared by a skilled person based on its common general knowledge.
  • the derivatives (IV) can be prepared according to the following literature references:
  • R b and R c are independently hydrogen, C 1-6 alkyl, C 3 - 7 cycloalkyl, C 3 - 7 cycloalkyl C 1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, hydroxy, C 1-6 alkoxy, halogen, heteroalkyl, heteroalkoxy, nitro, cyano, amino or mono- or di-C 1-6 alkyl substituted amino.
  • X is chloro, bromo or iodo.
  • Tetralones (VII) can be methylated and dehydrated to give the dihydro naphthaline derivative (II).
  • Aromatization of compound (II) can be effected with 3,4,5,6- tetrachloro-l,2-benzoquinone to give the methylnaphthalenyl derivative (III) which can be chlorinated or brominated using N-chlorosuccinimide of N- bromosuccinimide, respectively, to give the chloro- or bromo- naphthalenylderivatives (IV).
  • the process is described in G.A. Potter et al., PCT Int. Appl. (1999), WO9940944.
  • the starting materials of formula V are commercially available or can be prepared by a skilled person based on its common general knowledge.
  • the starting materials of formula V can be prepared according to the following literature:
  • the compounds of formula (I) are active compounds and inhibit chymase. These compounds consequently prevent the activation of Angiotensin II, Endothelin, TGFb, 111, SCF, collagenase and degradation of proteins like Thrombin, FN, APO Al ,2.
  • fibrotic diseases such as allergy, asthma, peripheral arterial occlusive disease, critical limb ischemia, vulnerable atherosclerotic plaque patients, unstable angina, congestive heart failure, left ventricular hypertrophy, ischemia reperfusion injury, stroke, cardiomyopathy, restenosis, rheumatoid arthritis, diabetic nephropathy, irritable Bowel Disease, Crohns' disease, atherothrombosis and/or burns/ulcers in Diabetes/CLI.
  • allergic, inflammatory and/or fibrotic diseases such as allergy, asthma, peripheral arterial occlusive disease, critical limb ischemia, vulnerable atherosclerotic plaque patients, unstable angina, congestive heart failure, left ventricular hypertrophy, ischemia reperfusion injury, stroke, cardiomyopathy, restenosis, rheumatoid arthritis, diabetic nephropathy, irritable Bowel Disease, Crohns' disease, atherothrombosis and/or burns/ulcers in Diabetes/CLI
  • the invention therefore also relates to pharmaceutical compositions comprising a compound as defined above and a pharmaceutically acceptable excipient.
  • the invention likewise embraces compounds as described above for use as therapeutically active substances, especially as therapeutically active substances for the treatment and/or prophylaxis of allergic, inflammatory and/or fibrotic diseases, particularly as therapeutically active substances for the treatment and/or prophylaxis of allergy, asthma, peripheral arterial occlusive disease, critical limb ischemia, vulnerable atherosclerotic plaque patients, unstable angina, congestive heart failure, left ventricular hypertrophy, ischemia reperfusion injury, stroke, cardiomyopathy, restenosis, rheumatoid arthritis, diabetic nephropathy, irritable Bowel Disease, Crohns' disease, atherothrombosis and/or burns/ulcers in Diabetes/CLI.
  • the invention also relates to the use of compounds as described above for the preparation of medicaments for the therapeutic and/or prophylactic treatment of allergic, inflammatory and/or fibrotic diseases, particularly for the therapeutic and/or prophylactic treatment of allergy, asthma, peripheral arterial occlusive disease, critical limb ischemia, vulnerable atherosclerotic plaque patients, unstable angina, congestive heart failure, left ventricular hypertrophy, ischemia reperfusion injury, stroke, cardiomyopathy, restenosis, rheumatoid arthritis, diabetic nephropathy, irritable Bowel Disease, Crohns' disease, atherothrombosis and/or burns/ulcers in Diabetes/CLI.
  • Such medicaments comprise a compound as described above.
  • the invention also relates to the process and the intermediates for manufacturing the compounds of formula (I) as well as the process for manufacturing the intermediates.
  • the inhibition of chymase by the compounds of the present invention can be demonstrated by the peptide substrate assay as described hereinafter.
  • a substrate was chosen containing the 4 amino acid peptide AAPF as a standard substrate for chymotrypsin like compounds (succinyl-Ala-Ala-Pro- Phe-[7-amino-4-methylcoumarin]; Lockhart BE, et al., "Recombinant human mast- cell chymase: an improved procedure for expression in Pichia pastoris and purification of the highly active enzyme.” Biotechnol Appl Biochem. published as immediate publication 26 May 2004 as manuscript BA20040074)) .
  • the peptide was synthesized with a purity of 95% from Bachem, Bubendorf, Switzerland).
  • Chymase purified form human skin mast cells was obtained from Calbiochem (Merck Biosciences, San Diego, California, USA).
  • the assay buffer was 0.15 M NaCl, 0.05M, Tris HCl , 0.05% CHAPS (3-[(3-Cholamidopropyl)-dimethylammonio]-l- propane sulphonate), O.lmg/ml Heparin (Heparin sodium, Sigma, porcine intestinal mucosa), 0.02mM AAPF- substrate, InM Chymase at pH 7.4.
  • the assay was performed in 96- well plates (Packard Optiplate), with a 0.05ml volume at room temperature.
  • Chymase activity was indicated by the initial rate of increase in fluorescence at 340/440nm (excitation / emission) from free 7-amino-4- methylcoumarin released from the substrate. Inhibition of the activity by inhibitory compounds was read after 30 min pre- incubation with the chymase at room temperature in assay buffer without AAPF-substrate. The assay was then started by addition of the indicated concentration of AAPF-substrate.
  • the IC50 values of the active compounds of the present invention preferably amount to about 1000 to 0.1 nM, especially about 40 to 0.1 nM.
  • the compounds of formula (I) and/or their pharmaceutically acceptable salts can be used as medicaments, e.g. in the form of pharmaceutical preparations for enteral, parenteral or topical administration. They can be administered, for example, perorally, e.g. in the form of tablets, coated tablets, dragees, hard and soft gelatine capsules, solutions, emulsions or suspensions, rectally, e.g. in the form of suppositories, parenterally, e.g. in the form of injection solutions or suspensions or infusion solutions, or topically, e.g. in the form of ointments, creams or oils. Oral administration is preferred.
  • the production of the pharmaceutical preparations can be effected in a manner which will be familiar to any person skilled in the art by bringing the described compounds of formula I and/or their pharmaceutically acceptable salts, optionally in combination with other therapeutically valuable substances, into a galenical administration form together with suitable, non-toxic, inert, therapeutically compatible solid or liquid carrier materials and, if desired, usual pharmaceutical adjuvants.
  • Suitable carrier materials are not only inorganic carrier materials, but also organic carrier materials.
  • lactose, corn starch or derivatives thereof, talc, stearic acid or its salts can be used as carrier materials for tablets, coated tablets, dragees and hard gelatine capsules.
  • Suitable carrier materials for soft gelatine capsules are, for example, vegetable oils, waxes, fats and semi-solid and liquid polyols (depending on the nature of the active ingredient no carriers might, however, be required in the case of soft gelatine capsules).
  • Suitable carrier materials for the production of solutions and syrups are, for example, water, polyols, sucrose, invert sugar.
  • Suitable carrier materials for injection solutions are, for example, water, alcohols, polyols, glycerol and vegetable oils.
  • Suitable carrier materials for suppositories are, for example, natural or hardened oils, waxes, fats and semi-liquid or liquid polyols.
  • Suitable carrier materials for topical preparations are glycerides, semi- synthetic and synthetic glycerides, hydrogenated oils, liquid waxes, liquid paraffins, liquid fatty alcohols, sterols, polyethylene glycols and cellulose derivatives.
  • Usual stabilizers preservatives, wetting and emulsifying agents, consistency- improving agents, flavour-improving agents, salts for varying the osmotic pressure, buffer substances, solubilizers, colorants and masking agents and antioxidants come into consideration as pharmaceutical adjuvants.
  • the dosage of the compounds of formula (I) can vary within wide limits depending on the disease to be controlled, the age and the individual condition of the patient and the mode of administration, and will, of course, be fitted to the individual requirements in each particular case. For adult patients a daily dosage of about 1 to 1000 mg, especially about 1 to 300 mg, comes into consideration. Depending on severity of the disease and the precise pharmacokinetic profile the compound could be administered with one or several daily dosage units, e.g. in 1 to 3 dosage units.
  • the pharmaceutical preparations conveniently contain about 1-500 mg, preferably 1-100 mg, of a compound of formula (I).
  • Film coated tablets containing the following ingredients can be manufactured in a conventional manner:
  • the active ingredient is sieved and mixed with microcristalline cellulose and the mixture is granulated with a solution of polyvinylpyrrolidon in water.
  • the granulate is mixed with sodium starch glycolate and magesiumstearate and compressed to yield kernels of 120 or 350 mg respectively.
  • the kernels are lacquered with an aqueous solution / suspension of the above mentioned film coat.
  • Capsules containing the following ingredients can be manufactured in a conventional manner: Ingredients Per capsule
  • the components are sieved and mixed and filled into capsules of size 2.
  • Injection solutions can have the following composition:
  • the active ingredient is dissolved in a mixture of Polyethylene Glycol 400 and water for injection (part).
  • the pH is adjusted to 5.0 by Acetic Acid.
  • the volume is adjusted to 1.0 ml by addition of the residual amount of water.
  • the solution is filtered, filled into vials using an appropriate overage and sterilized.
  • Soft gelatin capsules containing the following ingredients can be manufactured in a conventional manner:
  • the active ingredient is dissolved in a warm melting of the other ingredients and the mixture is filled into soft gelatin capsules of appropriate size.
  • the filled soft gelatin capsules are treated according to the usual procedures.
  • Sachets containing the following ingredients can be manufactured in a conventional manner:
  • Microcristalline cellulose (AVICEL PH 102) 1400.0 mg
  • Flavoring additives 1.0 mg
  • the active ingredient is mixed with lactose, microcristalline cellulose and sodium carboxymethyl cellulose and granulated with a mixture of polyvinylpyrrolidon in water.
  • the granulate is mixed with magnesiumstearate and the flavouring additives and filled into sachets.

Abstract

La présente invention concerne de nouveaux dérivés de pyrrole à cycles fusionnés de formule (I) où A, Ar, R1, R2, R2' et R2'' et n sont tels que définis dans la description et dans les revendications, de même que des sels de qualité physiologique desdits composés. Ces composés inhibent la chymase et peuvent être employés en tant que médicaments.
PCT/EP2006/069292 2005-12-15 2006-12-05 Nouveaux dérivés de pyrrole à cycles fusionnés WO2007068621A1 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
KR1020087014264A KR101355754B1 (ko) 2005-12-15 2006-12-05 신규 융합 피롤 유도체
NZ568594A NZ568594A (en) 2005-12-15 2006-12-05 Novel fused pyrrole derivatives for inhibition of chymase
CA002637740A CA2637740A1 (fr) 2005-12-15 2006-12-05 Derives de pyrrole a cycles fusionnes
EP06841282.4A EP1966134B1 (fr) 2005-12-15 2006-12-05 Nouveaux dérivés de pyrrole à cycles fusionnés
AU2006326136A AU2006326136B2 (en) 2005-12-15 2006-12-05 Novel fused pyrrole derivatives
BRPI0619963-1A BRPI0619963A2 (pt) 2005-12-15 2006-12-05 compostos derivados pirrólicos fundidos, composições farmacêuticas compreendendo os mesmos, bem como seus usos
JP2008544957A JP4955012B2 (ja) 2005-12-15 2006-12-05 新規な縮合ピロール誘導体
CN2006800471484A CN101351446B (zh) 2005-12-15 2006-12-05 稠合吡咯衍生物
IL191768A IL191768A0 (en) 2005-12-15 2008-05-27 Novel fused pyrrole derivatives
NO20082561A NO20082561L (no) 2005-12-15 2008-06-02 Nye koblede pyrrolderivater
HK09106622.4A HK1127058A1 (en) 2005-12-15 2009-07-21 Fused pyrrole derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05112210.9 2005-12-15
EP05112210 2005-12-15

Publications (1)

Publication Number Publication Date
WO2007068621A1 true WO2007068621A1 (fr) 2007-06-21

Family

ID=37782002

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/069292 WO2007068621A1 (fr) 2005-12-15 2006-12-05 Nouveaux dérivés de pyrrole à cycles fusionnés

Country Status (21)

Country Link
US (1) US7696240B2 (fr)
EP (1) EP1966134B1 (fr)
JP (1) JP4955012B2 (fr)
KR (1) KR101355754B1 (fr)
CN (1) CN101351446B (fr)
AR (1) AR058338A1 (fr)
AU (1) AU2006326136B2 (fr)
BR (1) BRPI0619963A2 (fr)
CA (1) CA2637740A1 (fr)
CR (1) CR10027A (fr)
EC (1) ECSP088549A (fr)
HK (1) HK1127058A1 (fr)
IL (1) IL191768A0 (fr)
MA (1) MA30162B1 (fr)
MY (1) MY146491A (fr)
NO (1) NO20082561L (fr)
NZ (1) NZ568594A (fr)
RU (1) RU2434853C2 (fr)
TW (1) TWI363755B (fr)
UA (1) UA95788C2 (fr)
WO (1) WO2007068621A1 (fr)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008005456A2 (fr) * 2006-06-30 2008-01-10 Sepracor Inc. Inhibiteurs hétérocycliques fusionnés de la d-aminoacide-oxydase
WO2008028118A1 (fr) * 2006-08-31 2008-03-06 Smithkline Beecham Corporaiton Composés chimiques
WO2008153129A1 (fr) * 2007-06-14 2008-12-18 Teijin Pharma Limited Agent pour abaisser le taux d'acide urique
US7579370B2 (en) 2006-06-30 2009-08-25 Sepracor Inc. Fused heterocycles
WO2010030500A1 (fr) * 2008-09-09 2010-03-18 Boehringer Ingelheim International Gmbh Inhibiteurs d'aza-benzimidazolone chymase
US7884124B2 (en) 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
US7893098B2 (en) 2003-12-29 2011-02-22 Sepracor Inc. Pyrrole and pyrazole DAAO inhibitors
US7902252B2 (en) 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
US8053603B2 (en) 2006-01-06 2011-11-08 Sunovion Pharmaceuticals Inc. Tetralone-based monoamine reuptake inhibitors
US8097760B2 (en) 2006-03-31 2012-01-17 Sunovion Pharmacuticals Inc. Preparation of chiral amides and amines
US8669291B2 (en) 2007-05-31 2014-03-11 Sunovion Pharmaceuticals Inc. Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
EP2731439A1 (fr) * 2011-07-12 2014-05-21 Merck Sharp & Dohme Corp. INHIBITEURS DE LA KINASE TrkA, COMPOSITIONS EN CONTENANT ET MÉTHODES ASSOCIÉES
US8877975B2 (en) 2006-01-06 2014-11-04 Sunovion Pharmaceuticals Inc. Cycloalkylamines as monoamine reuptake inhibitors
US9035047B2 (en) 2007-04-16 2015-05-19 Abbvie Inc. 7-substituted indole Mcl-1 inhibitors

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1904066B1 (fr) 2005-07-06 2018-05-23 Sunovion Pharmaceuticals Inc. COMBINAISONS D'ESZOPICLONE ET DE TRANS 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-N-METHYL-1-NAPHTALENAMINE OR TRANS 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPHTALENAMINE, pour le TRAITEMENT DE LA MENOPAUSE, perimenopause ET des TROUBLES COGNITIFS
WO2007047146A2 (fr) * 2005-10-11 2007-04-26 Intermune, Inc. Inhibiteurs de réplication virale
US20080058395A1 (en) * 2006-06-30 2008-03-06 Sepracor Inc. Fused heterocyclic inhibitors of D-amino acid oxidase
JP2010516697A (ja) * 2007-01-18 2010-05-20 セプラコール インク． Ｄ−アミノ酸オキシダーゼ阻害剤
MX2009008439A (es) * 2007-02-12 2009-08-13 Intermune Inc Nuevos inhibidores de la replicacion del virus de hepatitis c.
US20100120740A1 (en) * 2008-08-07 2010-05-13 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
WO2011017634A2 (fr) * 2009-08-07 2011-02-10 Sepracore Inc. Promédicaments d'inhibiteurs hétérocycliques fusionnés de la d-aminoacide oxydase
NZ600748A (en) 2009-12-25 2014-06-27 Daiichi Sankyo Co Ltd Seven-membered ring compound and pharmaceutical use therefor
KR101739259B1 (ko) 2015-04-22 2017-05-25 광운대학교 산학협력단 신규 피롤 단량체 및 그 제조방법, 피롤 단량체로부터 합성된 고분자 또는 화합물 및 그 제조방법
EP3370518B1 (fr) 2015-10-14 2023-08-23 X-Therma, Inc. Compositions et procédés permettant de réduire la formation de cristaux de glace
US20200262794A1 (en) * 2015-12-07 2020-08-20 Wake Forest University Health Sciences Glycolate oxidase inhibitors and methods of use for the treatment of kidney stones
EP3615025A4 (fr) * 2017-04-26 2020-11-25 The Board of Trustees of the University of Illionis Activateurs de nrf et de hif/inhibiteurs de hdac et méthodes thérapeutiques utilisant ceux-ci
US11690824B2 (en) 2018-04-10 2023-07-04 The General Hospital Corporation Antibacterial compounds
CN112028815A (zh) * 2019-06-03 2020-12-04 中国药科大学 吲哚类衍生物及其医药用途

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997008155A1 (fr) * 1995-08-31 1997-03-06 Novartis Ag Nouveaux derives de 2,3-dioxo-1,2,3,4-tetrahydro-quinoxalinyle
WO1997019077A1 (fr) 1995-11-23 1997-05-29 MERCK Patent Gesellschaft mit beschränkter Haftung Antagonistes des recepteurs de l'endotheline
WO1997035572A1 (fr) 1996-03-28 1997-10-02 Smithkline Beecham Corporation Inhibiteurs de chimiokines a base d'indole-acide carboxylique
US5684032A (en) 1994-12-13 1997-11-04 Smithkline Beecham Corporation Compounds
US5686481A (en) 1993-12-21 1997-11-11 Smithkline Beecham Corporation Endothelin receptor antagonists
WO1999007351A2 (fr) 1997-08-07 1999-02-18 Zeneca Limited Composes chimiques
WO1999007678A1 (fr) 1997-08-07 1999-02-18 Zeneca Limited Derives d'indole utiles en tant qu'antagonistes du recepteur mcp-1
WO2000044753A1 (fr) 1999-01-29 2000-08-03 Vernalis Research Limited Derives de pirazino(aza)indole
WO2000046195A1 (fr) 1999-02-05 2000-08-10 Astrazeneca Ab Derives d'indole anti-inflammatoires
WO2002030895A1 (fr) 2000-10-10 2002-04-18 Smithkline Beecham Corporation Indoles substituees, compositions pharmaceutiques contenant ces indoles et leur utilisation comme agent de fixation de ppar-$g(g)
WO2005005415A1 (fr) 2003-07-09 2005-01-20 Biolipox Ab Indoles utilises dans le traitement de l'inflammation
WO2005123673A1 (fr) * 2004-06-18 2005-12-29 Biolipox Ab Indoles utilises dans le traitement d'inflammations
WO2006125324A1 (fr) * 2005-05-27 2006-11-30 Queen's University At Kingston Traitement de troubles du repliement des proteines

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4169108A (en) * 1973-08-16 1979-09-25 Sterling Drug Inc. 5(OR 6)-[(Substituted-amino)alkyl]-2,3-naphthalenediols
DK0633886T3 (da) 1992-04-03 2000-12-18 Upjohn Co Farmaceutisk aktive bicyclisk-heterocycliske aminer
GB9225141D0 (en) 1992-12-01 1993-01-20 Smithkline Beecham Corp Chemical compounds
US6169107B1 (en) * 1993-04-28 2001-01-02 Sumitomo Pharmaceutical Co., Ltd. Indoloylguanidine derivatives
DE4326005A1 (de) 1993-08-03 1995-02-09 Hoechst Ag Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament
EP0639573A1 (fr) 1993-08-03 1995-02-22 Hoechst Aktiengesellschaft Hétérocycles à cinq chaînons benzocondensés, procédé pour leur préparation, leur utilisation comme médicament et comme diagnostique aussi bien que les produits pharmaceutiques le contenant
US5852046A (en) * 1993-08-03 1998-12-22 Hoechst Aktiengesellschaft Benzo-fused heterocyclic compounds having a 5-membered ring processes for their preparation their use as medicaments their use as diagnostic agents and medicaments containing them
CA2194984C (fr) 1994-07-26 2002-07-02 John Eugene Macor Derives 4-indole utilises comme agonistes et antagonistes de la serotonine
CA2196046A1 (fr) 1994-07-27 1996-02-08 Nigel Birdsall Composes heterocycliques utiles comme effecteurs allosteriques au niveau des recepteurs muscariniques
FR2726268B1 (fr) * 1994-10-26 1996-12-06 Adir Nouvelles o-arylmethyl n-(thio)acyl hydroxylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent
AU4514496A (en) 1994-12-13 1996-07-03 Smithkline Beecham Corporation Novel compounds
ATE334668T1 (de) 1996-05-31 2006-08-15 Allelix Neuroscience Inc Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
FR2754262B1 (fr) 1996-10-08 1998-10-30 Synthelabo Derives de 1h-pyrido[3,4-b]indole-4-carboxamide, leur preparation et leur application en therapeutique
JPH10114654A (ja) 1996-10-09 1998-05-06 Fujisawa Pharmaceut Co Ltd 新規用途
AR013084A1 (es) 1997-06-19 2000-12-13 Astrazeneca Ab Derivados de amidino utiles como inhibidores de la trombina, composicion farmaceutica, utilizacion de dichos compuestos para la preparacion demedicamentos y proceso para la preparacion de los compuestos mencionados
FR2768146B1 (fr) 1997-09-05 2000-05-05 Oreal Nouveaux composes de la famille des indole-carboxyliques et leur utilisation
WO1999036422A1 (fr) 1998-01-14 1999-07-22 The Uab Research Foundation Procede de synthese et de criblage d'inhibiteurs d'enzyme synthetase nad bacterienne, composes a base de cette enzyme et procedes de traitement des infections bacteriennes et microbiennes au moyen d'inhibiteurs de ladite enzyme
DE69909073T2 (de) 1998-02-12 2004-05-19 De Montfort University Durch hydroxylierung aktivierte wirkstofffreigabe
US6500853B1 (en) * 1998-02-28 2002-12-31 Genetics Institute, Llc Inhibitors of phospholipase enzymes
CA2335254A1 (fr) 1998-07-08 2000-01-20 Harbor Branch Oceanographic Institution, Inc. Derives du bis-indole et leur utilisation comme agents anti-inflammatoires
US6589975B2 (en) * 1998-07-08 2003-07-08 The Regents Of The University Of California Synthetic compounds for treatment of inflammation
TR200100047T2 (tr) * 1998-07-15 2001-10-22 Teijin Limited Tiyobenzimidazol türevleri
US6325991B1 (en) 1998-08-24 2001-12-04 Susan E. Draheim Methods and compositions for treating periodontal disease with an inhibitor of secretory phospholipase A2
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
GB9902455D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902453D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
FR2796274B1 (fr) * 1999-07-16 2001-09-21 Oreal Utilisation de l'acide 4,6-dimethoxy-indole 2-carboxylique ou de ses derives pour stimuler ou induire la pousse des cheveux et/ou stopper leur chute
AU7962200A (en) * 1999-10-29 2001-05-14 Wakunaga Pharmaceutical Co., Ltd Novel indole derivatives and drugs containing the same as the active ingredient
US20030187261A1 (en) 2000-01-07 2003-10-02 Libor Havlicek Purine derivatives, process for their preparation and use thereof
EP1249450B1 (fr) * 2000-01-17 2007-10-10 Teijin Pharma Limited Derives benzimidazoles comme inhibiteurs de chymase humaine
US20030083315A1 (en) * 2000-01-17 2003-05-01 Naoki Tsuchiya Human chymase inhibitors
KR100539139B1 (ko) 2000-07-31 2005-12-26 에프. 호프만-라 로슈 아게 피페라진 유도체
EP1792614A1 (fr) 2001-02-22 2007-06-06 Teijin Pharma Limited Dérivés de benzo[b]thiophène
US6710068B2 (en) 2001-04-11 2004-03-23 Idenix Pharmaceuticals, Inc. Phenylindoles for the treatment of HIV
TWI317634B (en) * 2001-12-13 2009-12-01 Nat Health Research Institutes Aroyl indoles compounds
WO2004080965A1 (fr) 2003-03-14 2004-09-23 Kyowa Hakko Kogyo Co., Ltd. Antagoniste du recepteur du neuropeptide ff
US7265148B2 (en) 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US7396940B2 (en) * 2003-10-23 2008-07-08 Hoffmann-La Roche Inc. Combinatorial library of 3-aryl-1H-indole-2-carboxylic acid
US20050089936A1 (en) * 2003-10-23 2005-04-28 Jianping Cai Combinatorial library of 3-aryl-1H-indole-2-carboxylic acid amides

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686481A (en) 1993-12-21 1997-11-11 Smithkline Beecham Corporation Endothelin receptor antagonists
US5684032A (en) 1994-12-13 1997-11-04 Smithkline Beecham Corporation Compounds
WO1997008155A1 (fr) * 1995-08-31 1997-03-06 Novartis Ag Nouveaux derives de 2,3-dioxo-1,2,3,4-tetrahydro-quinoxalinyle
WO1997019077A1 (fr) 1995-11-23 1997-05-29 MERCK Patent Gesellschaft mit beschränkter Haftung Antagonistes des recepteurs de l'endotheline
WO1997035572A1 (fr) 1996-03-28 1997-10-02 Smithkline Beecham Corporation Inhibiteurs de chimiokines a base d'indole-acide carboxylique
WO1999007678A1 (fr) 1997-08-07 1999-02-18 Zeneca Limited Derives d'indole utiles en tant qu'antagonistes du recepteur mcp-1
WO1999007351A2 (fr) 1997-08-07 1999-02-18 Zeneca Limited Composes chimiques
WO2000044753A1 (fr) 1999-01-29 2000-08-03 Vernalis Research Limited Derives de pirazino(aza)indole
WO2000046195A1 (fr) 1999-02-05 2000-08-10 Astrazeneca Ab Derives d'indole anti-inflammatoires
WO2002030895A1 (fr) 2000-10-10 2002-04-18 Smithkline Beecham Corporation Indoles substituees, compositions pharmaceutiques contenant ces indoles et leur utilisation comme agent de fixation de ppar-$g(g)
WO2005005415A1 (fr) 2003-07-09 2005-01-20 Biolipox Ab Indoles utilises dans le traitement de l'inflammation
WO2005123673A1 (fr) * 2004-06-18 2005-12-29 Biolipox Ab Indoles utilises dans le traitement d'inflammations
WO2006125324A1 (fr) * 2005-05-27 2006-11-30 Queen's University At Kingston Traitement de troubles du repliement des proteines

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
ARNAIZ D O ET AL: "Design, synthesis, and in vitro biological activity of indole-based factor Xa inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 10, no. 9, May 2000 (2000-05-01), pages 957 - 961, XP004199051, ISSN: 0960-894X *
BENNASAR M -LLUISA ET AL: "A new radical-based route to calothrixin B", ORGANIC LETTERS, vol. 8, no. 4, February 2006 (2006-02-01), pages 561 - 564, XP002424094, ISSN: 1523-7060 *
BOEKELHEIDE V. ET AL., JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 72, 1950, pages 2134 - 7
DOGGRELL SA; WANSTALL JC, CAN J PHYSIOL PHARMACOL., vol. 83, no. 2, February 2005 (2005-02-01), pages 123 - 30
FORBES, E.J.: "The oxidation of 3,4-dihydroxyphenethylamines", JOURNAL OF THE CHEMICAL SOCIETY, 1956, pages 513 - 517, XP009080497 *
GRIESSBACH KLAUS ET AL., ARCHIV DER PHARMAZIE, vol. 335, no. 11-12, January 2002 (2002-01-01), pages 547 - 555
GRIESSBACH KLAUS ET AL: "Structure-activity relationship studies of 1-substituted 3-dodecanoylindole-2-carboxylic acids as inhibitors of cytosolic phospholipase A2-mediated arachidonic acid release in intact platelets.", ARCHIV DER PHARMAZIE (WEINHEIM), vol. 335, no. 11-12, January 2002 (2002-01-01), pages 547 - 555, XP002424093, ISSN: 0365-6233 *
J. MARCH: "Advanced Organic Chemistry", 1992, JOHN WILEY AND SONS
LINDSTEDT KA; KOVANEN PT, CURR OPIN LIPIDOL., vol. 15, no. 5, October 2004 (2004-10-01), pages 567 - 73
RAYMOND, W. W.; S. W. RUGGLES ET AL., JBC, vol. 278, no. 36, 2003, pages 34517 - 34524
REED CE; KITA H.J, ALLERGY CLIN IMMUNOL., vol. 114, no. 5, November 2004 (2004-11-01), pages 997 - 1008
SEMPRONJ: "FORMAZIONE DI FENILIDRAZIONI ISOMERI NELLA REAZIONE DI JAPP-KLINGEMANN", GAZZETTA CHIMICA ITALIANA, SOCIETA CHIMICA ITALIANA, ROME, IT, vol. 68, 1938, pages 263 - 271, XP009080248, ISSN: 0016-5603 *
TAKAI S ET AL., EUR J PHARMACOL., vol. 501, no. 1-3, 6 October 2004 (2004-10-06), pages 1 - 8
TAKAI S ET AL., TRENDS PHARMACOL SCI., vol. 25, no. 10, October 2004 (2004-10-01), pages 518 - 22
TAKAI S; MIYAZAKI M., CURR VASC PHARMACOL., vol. 1, no. 2, June 2003 (2003-06-01), pages 217 - 24

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7893098B2 (en) 2003-12-29 2011-02-22 Sepracor Inc. Pyrrole and pyrazole DAAO inhibitors
US8877975B2 (en) 2006-01-06 2014-11-04 Sunovion Pharmaceuticals Inc. Cycloalkylamines as monoamine reuptake inhibitors
US10562878B2 (en) 2006-01-06 2020-02-18 Sunovion Pharamceuticals Inc. Cycloalkylamines as monoamine reuptake inhibitors
US9868718B2 (en) 2006-01-06 2018-01-16 Sunovion Pharmaceuticals Inc. Cycloalkylamines as monoamine reuptake inhibitors
US8053603B2 (en) 2006-01-06 2011-11-08 Sunovion Pharmaceuticals Inc. Tetralone-based monoamine reuptake inhibitors
US8097760B2 (en) 2006-03-31 2012-01-17 Sunovion Pharmacuticals Inc. Preparation of chiral amides and amines
WO2008005456A3 (fr) * 2006-06-30 2008-07-31 Sepracor Inc Inhibiteurs hétérocycliques fusionnés de la d-aminoacide-oxydase
US7579370B2 (en) 2006-06-30 2009-08-25 Sepracor Inc. Fused heterocycles
US7884124B2 (en) 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
WO2008005456A2 (fr) * 2006-06-30 2008-01-10 Sepracor Inc. Inhibiteurs hétérocycliques fusionnés de la d-aminoacide-oxydase
WO2008028118A1 (fr) * 2006-08-31 2008-03-06 Smithkline Beecham Corporaiton Composés chimiques
US7902252B2 (en) 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
US9035047B2 (en) 2007-04-16 2015-05-19 Abbvie Inc. 7-substituted indole Mcl-1 inhibitors
US9359296B2 (en) 2007-04-16 2016-06-07 Abbvie Inc. 7-substituted indole Mcl-1 inhibitors
US8669291B2 (en) 2007-05-31 2014-03-11 Sunovion Pharmaceuticals Inc. Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
US9586888B2 (en) 2007-05-31 2017-03-07 Sunovion Pharmaceuticals Inc. Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
WO2008153129A1 (fr) * 2007-06-14 2008-12-18 Teijin Pharma Limited Agent pour abaisser le taux d'acide urique
US9062056B2 (en) 2008-09-09 2015-06-23 Boehringer Ingelheim International Gmbh Aza-benzimidazolone Chymase inhibitors
WO2010030500A1 (fr) * 2008-09-09 2010-03-18 Boehringer Ingelheim International Gmbh Inhibiteurs d'aza-benzimidazolone chymase
EP2731439A1 (fr) * 2011-07-12 2014-05-21 Merck Sharp & Dohme Corp. INHIBITEURS DE LA KINASE TrkA, COMPOSITIONS EN CONTENANT ET MÉTHODES ASSOCIÉES
EP2731439A4 (fr) * 2011-07-12 2014-12-03 Merck Sharp & Dohme INHIBITEURS DE LA KINASE TrkA, COMPOSITIONS EN CONTENANT ET MÉTHODES ASSOCIÉES
US9102673B2 (en) 2011-07-12 2015-08-11 Merck Sharp & Dohme Corp. Substituted pyrrolo[3,2-c]pyridines as TrkA kinase inhibitors

Also Published As

Publication number Publication date
RU2434853C2 (ru) 2011-11-27
HK1127058A1 (en) 2009-09-18
AR058338A1 (es) 2008-01-30
CN101351446B (zh) 2011-10-05
NZ568594A (en) 2011-08-26
TW200732303A (en) 2007-09-01
IL191768A0 (en) 2008-12-29
UA95788C2 (en) 2011-09-12
JP2009519291A (ja) 2009-05-14
US20070142452A1 (en) 2007-06-21
KR101355754B1 (ko) 2014-01-27
MA30162B1 (fr) 2009-01-02
BRPI0619963A2 (pt) 2011-10-25
CR10027A (es) 2008-07-29
MY146491A (en) 2012-08-15
KR20080070062A (ko) 2008-07-29
US7696240B2 (en) 2010-04-13
EP1966134B1 (fr) 2014-03-12
CN101351446A (zh) 2009-01-21
NO20082561L (no) 2008-08-27
RU2008128347A (ru) 2010-01-20
EP1966134A1 (fr) 2008-09-10
JP4955012B2 (ja) 2012-06-20
TWI363755B (en) 2012-05-11
AU2006326136A1 (en) 2007-06-21
CA2637740A1 (fr) 2007-06-21
ECSP088549A (es) 2008-07-30
AU2006326136B2 (en) 2012-08-16

Similar Documents

Publication Publication Date Title
EP1966134B1 (fr) Nouveaux dérivés de pyrrole à cycles fusionnés
US7807659B2 (en) Caspase inhibitors and uses thereof
EP1725555B1 (fr) Hydrazides d'acide pyrrolopyridine-2-carboxylique utilises comme inhibiteurs de la glycogene phosphorylase
BRPI0108396B1 (pt) Derivados de pirimidina-4-ona como inibidores de ldl-pla2
FR2804114A1 (fr) Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
FR2722190A1 (fr) Derives de 1-benzyl-1,3-dihydro-2h-benzimidazol-2-one, leur preparation, les compositions pharmaceutique en contenant
FR2927625A1 (fr) Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique
US7612099B2 (en) Vinylogous acid derivatives
US6291679B1 (en) Process for preparing benzoperhydroisoindole compounds
JP2022081702A (ja) ピラゾール化合物
AU2007306399B2 (en) Vinylogous acids derivatives as chymase inhibitors
KR100236852B1 (ko) 플루오로 퀴놀린 유도체

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680047148.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2006841282

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 568594

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 191768

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: CR2008-010027

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 08055477

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 2006326136

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 12008501314

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2637740

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/007475

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2008544957

Country of ref document: JP

Ref document number: 2990/CHENP/2008

Country of ref document: IN

Ref document number: 1020087014264

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2008060997

Country of ref document: EG

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2006326136

Country of ref document: AU

Date of ref document: 20061205

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006326136

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2008128347

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2006841282

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0619963

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080617